Eileen E. Parkes - Concepedia

Author

Eileen E. Parkes

University of Oxford ORCID

Also Known As

E. E. Parkes, E. Parkes, E.E. Parkes, EE Parkes, Eileen E Parkes, Eileen E. Parkes, Eileen Parkes, Emily Parkes

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

University of Oxford Queen's University Belfast Almac (United Kingdom)Belfast Health and Social Care Trust Institute of Cancer Research

About

Eileen E. Parkes is an author at University of Oxford specializing in immunology, tumor biology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	103
2	Immunology	3	3	103
3	Engineering	1	1	57
4	Allergy	1	1	13
5	Cell Biology	1	1	33

Eileen E. Parkes

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer Eileen E. Parkes, Steven M. Walker, Laura E. Taggart, JNCI Journal of the National Cancer Institute	2016	447
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis Jun Li, Mercedes A. Duran Paez, Ninjit Dhanota, Cancer Discovery	2020	264
Non-cell-autonomous cancer progression from chromosomal instability Jun Li, Melissa J. Hubisz, Ethan M. Earlie, Nature	2023	242
Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model Yiannis Philippou, Hanna Sjoberg, Emma Murphy, British Journal of Cancer	2020	72
Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer Matthew P. Humphries, Seán O. Hynes, Victoria Bingham, Journal of Oncology Breast OncologyEngineeringDigital PathologyImmunologyPathology	2018	57
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway Jan Pěnčík, C. Philippe, Michaela Schlederer, Molecular Cancer	2023	51
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial Priyanka Sharma, William E. Barlow, Andrew K. Godwin, Journal of Clinical Oncology	2019	48
The clinical and molecular significance associated with STING signaling in breast cancer Eileen E. Parkes, Matthew P. Humphries, Elaine S. Gilmore, npj Breast Cancer	2021	35
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer Eileen E. Parkes, Kienan I. Savage, T F Lioe, British Journal of Cancer	2021	34
A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer Niamh E. Buckley, Paula Haddock, Ricardo De Matos Simoes, Oncotarget Breast OncologyImmunologyBrca1-mutant Breast CancersCancer BiologyTumor Biology	2016	33

Page 1